News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,607 Results
Type
Article (43552)
Company Profile (361)
Press Release (657694)
Section
Business (207541)
Career Advice (2004)
Deals (35885)
Drug Delivery (98)
Drug Development (83671)
Employer Resources (170)
FDA (16567)
Job Trends (15058)
News (351881)
Policy (33170)
Tag
Academia (2662)
Alliances (50384)
Alzheimer's disease (1273)
Approvals (16471)
Artificial intelligence (129)
Bankruptcy (356)
Best Places to Work (11701)
Biotechnology (259)
Breast cancer (117)
Cancer (1030)
Cardiovascular disease (88)
Career advice (1672)
Cell therapy (242)
Clinical research (66132)
Collaboration (362)
Compensation (178)
COVID-19 (2605)
C-suite (91)
Data (956)
Diabetes (150)
Diagnostics (6239)
Earnings (85369)
Employer resources (148)
Events (112006)
Executive appointments (262)
FDA (17039)
Funding (315)
Gene therapy (176)
GLP-1 (622)
Government (4435)
Healthcare (19164)
Infectious disease (2684)
Inflammatory bowel disease (110)
Interviews (310)
IPO (16509)
Job creations (3688)
Job search strategy (1427)
Layoffs (437)
Legal (7949)
Lung cancer (170)
Manufacturing (169)
Medical device (13391)
Medtech (13396)
Mergers & acquisitions (19412)
Metabolic disorders (412)
Neuroscience (1531)
NextGen Class of 2024 (6701)
Non-profit (4563)
Northern California (1318)
Obesity (243)
Opinion (193)
Patents (99)
People (57215)
Phase I (20573)
Phase II (29077)
Phase III (21743)
Pipeline (326)
Postmarket research (2710)
Preclinical (8777)
Radiopharmaceuticals (250)
Rare diseases (208)
Real estate (5994)
Regulatory (22050)
Research institute (2414)
Resumes & cover letters (352)
Southern California (1174)
Startups (3693)
United States (12623)
Vaccines (570)
Weight loss (189)
Date
Today (259)
Last 7 days (1094)
Last 30 days (3373)
Last 365 days (36677)
2024 (32111)
2023 (41051)
2022 (52296)
2021 (56829)
2020 (55103)
2019 (47639)
2018 (35958)
2017 (33035)
2016 (32438)
2015 (38445)
2014 (32164)
2013 (27177)
2012 (29331)
2011 (30045)
2010 (28196)
Location
Africa (741)
Arizona (193)
Asia (38386)
Australia (6345)
California (3000)
Canada (1213)
China (231)
Colorado (131)
Connecticut (134)
Europe (84276)
Florida (425)
Georgia (111)
Illinois (333)
Indiana (191)
Kansas (99)
Maryland (552)
Massachusetts (2470)
Michigan (146)
Minnesota (260)
New Jersey (882)
New York (887)
North Carolina (730)
Northern California (1318)
Ohio (132)
Pennsylvania (791)
South America (1116)
Southern California (1174)
Texas (413)
Utah (85)
Washington State (345)
701,607 Results for "biorestorative therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York.
June 4, 2024
·
3 min read
Pharm Country
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
BioRestorative Therapies, Inc. reported that it has had substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a license of BioRestorative’s allogeneic, off-the-shelf ThermoStem® metabolic intellectual property.
June 13, 2024
·
5 min read
Business
BioRestorative Therapies Provides First Quarter 2024 Business Update
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business.
May 14, 2024
·
6 min read
Press Releases
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
November 1, 2024
·
5 min read
Pharm Country
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
BioRestorative Therapies, Inc . is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135 related to the Company’s allogeneic, off-the-shelf ThermoStem® platform.
June 27, 2024
·
6 min read
Deals
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
BioRestorative Therapies, Inc. announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
June 17, 2024
·
4 min read
Press Releases
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 6, 2024
·
5 min read
Drug Development
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced its development of a novel exosome-based biologic program targeting obesity.
May 8, 2024
·
5 min read
Press Releases
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
October 10, 2024
·
3 min read
Business
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024.
April 30, 2024
·
3 min read
1 of 70,161
Next
